Ken Griffin Nuvectis Pharma, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 43,000 shares of NVCT stock, worth $424,409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,000Holding current value
$424,409% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding NVCT
# of Institutions
38Shares Held
2.62MCall Options Held
116KPut Options Held
87.6K-
Ronit Capital LLP563KShares$5.55 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA467KShares$4.61 Million0.0% of portfolio
-
Baldwin Brothers LLC358KShares$3.54 Million0.28% of portfolio
-
Iridian Asset Management LLC254KShares$2.51 Million0.82% of portfolio
-
Geode Capital Management, LLC Boston, MA135KShares$1.34 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $145M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...